TSC1 and TSC2 gene mutations and their implications for tratment in tuberous sclerosis complex : a review by Rosset, Clévia et al.
TSC1 and TSC2 gene mutations and their implications for treatment in
Tuberous Sclerosis Complex: a review
Clévia Rosset1,2, Cristina Brinckmann Oliveira Netto3 and Patricia Ashton-Prolla1,2,3,4
1Laboratório de Medicina Genômica, Centro de Pesquisa Experimental. Hospital de Clínicas de Porto
Alegre (HCPA), Porto Alegre, RS, Brazil.
2Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do
Sul (UFRGS), Porto Alegre, RS, Brazil.
3Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
4Departamento de Genética, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS,
Brazil.
Abstract
Tuberous sclerosis complex is an autosomal dominant disorder characterized by skin manifestations and formation
of multiple tumors in different organs, mainly in the central nervous system. Tuberous sclerosis is caused by the mu-
tation of one of two tumor suppressor genes, TSC1 or TSC2. Currently, the development of novel techniques and
great advances in high-throughput genetic analysis made mutation screening of the TSC1 and TSC2 genes more
widely available. Extensive studies of the TSC1 and TSC2 genes in patients with TSC worldwide have revealed a
wide spectrum of mutations. Consequently, the discovery of the underlying genetic defects in TSC has furthered our
understanding of this complex genetic disorder, and genotype-phenotype correlations are becoming possible, al-
though there are still only a few clearly established correlations. This review focuses on the main symptoms and ge-
netic alterations described in TSC patients from 13 countries in three continents, as well as on genotype-phenotype
correlations established to date. The determination of genotype-phenotype correlations may contribute to the estab-
lishment of successful personalized treatment for TSC.
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Tuberous Sclerosis Complex
Tuberous sclerosis, also known as Tuberous sclerosis
complex (TSC) is an autosomal dominant neurocutaneous
and progressive disorder, frequently characterized by the
occurrence of multiple tumors in different organs. Pene-
trance reaches 95% and is variable; expressivity also varies
greatly even within a given family (Northrup et al., 1993).
The incidence of TSC is 1/10,000 births, and its prevalence
in the general population of Europe has been estimated to
be 8.8/100,000 (Orphanet: Tuberous Sclerosis), affecting
multiple ethnic groups (Joinson et al., 2003).
Diagnosis and symptomatology
Tuberous sclerosis has been initially described by von
Recklinghausen in 1862. In 1908, Heinrich Vogt estab-
lished the diagnostic criteria for TSC as the so-called triad:
epilepsy, mental retardation and adenoma sebaceum. As
none of these clinical signs were pathognomonic for TSC,
clinical diagnostic criteria were revised by a consortium in
1998 (Roach et al., 1998), which proposed three diagnostic
categories (definite, probable or possible TSC) based on the
presence of major and/or minor features of the disease. Ta-
ble 1 shows the revised and updated diagnostic criteria for
TSC, established by the same consortium in 2012
(Northrup et al., 2013). A definite clinical diagnosis is
made when two major features, or one major feature plus
two minor features are present. Importantly, most major
features are localized to the skin and central nervous sys-
tem. Also, one must consider that the clinical manifesta-
tions of TSC appear at distinct developmental points, and a
person with suspected TSC may need multiple sequential
evaluations before a definite clinical diagnosis can be
made.
After skin and CNS findings, renal manifestations are
the most common abnormalities associated with TSC.
These include renal cell carcinoma, oncocytomas, angio-
myolipomas (in 80% of patients) and renal cystic disease
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(in 50% of the patients) (Dixon et al., 2011). Typically, re-
nal manifestations in children with TSC are first seen in in-
fancy and increase with age. Angiomyolipomas, one of the
leading causes of death in TSC patients, are multiple and
often bilateral. The associated mortality is due to complica-
tions when these lesions become very large. Another conse-
quence of angiomyolipomas is destruction of the normal
renal parenchyma, resulting in renal failure and end-stage
renal disease (Shepherd et al., 1991). Patients with clini-
cally detectable renal cystic disease usually have a severe
very early-onset polycystic phenotype (about 2% of TSC
patients) (Sampson et al., 1997).
Pulmonary involvement, specifically lymphangio-
leiomyomatosis (LAM), is the third most common cause of
TSC-associated morbidity, occurring in approximately
35% of female TSC patients. LAM is caused by prolifera-
tion of atypical smooth muscle cells in the peribronchial,
perivascular, and perilymphatic tissues of the lung
(Kumasaka et al., 2004). LAM occurs almost exclusively in
young women, typically presenting between 30 to 35 years
of age. Symptoms have been reported to begin or worsen
during pregnancy, suggesting that LAM may be
hormonally influenced (Castro et al., 1995).
Skin lesions are detected in 70% of patients with TSC
and include hypomelanotic macules, shagreen patches,
confetti-like lesions, forehead fibrous plaque, facial angio-
fibromas, and periungual and ungual fibromas (Schwartz et
al., 2007). Depending on studied population, even as many
as 100% of TSC patients younger than five years may pres-
ent with hypopigmented macules. An aggregation of red-
dish papules, appearing on the nose and cheeks in a charac-
teristic butterfly distribution, belongs to the Vogt triad of
signs. Although usually symmetrical, occasionally they
may be found unilaterally (Jozwiak et al., 1998). Facial
angiofibromas (adenoma sebaceum) are formed by hamar-
tomatous growth of dermal connective tissue with rich
vasculature and can result in decreased quality of life since
they affect appearance, may cause disfigurement, and are
prone to bleeding, which increases the possibility of infec-
tion (Yates, 2006). Shagreen Patches are areas of thick, ir-
regularly shaped, and elevated skin, usually found on the
lower back. Mean age of appearance is about 8.1 years (Sun
et al., 2005). Ungual and subungual fibromas are small tu-
mors that grow around and under toenails or fingernails.
Their mean age of appearance is 14.9 years (Sun et al.,
2005) and their prevalence in older patients (above 30
years) is close to 90%. Forehead plaques appear under the
age of 14 years (Jozwiak et al., 1998), with mean age of ap-
pearance being 2.6 years (Sun et al., 2005).
TSC is also associated with both retinal and non-
retinal ocular findings (Rowley et al., 2001). Hamartomas
are the most common retinal manifestation of TSC and are
identified in approximately 40 to 50% of individuals. For-
tunately, they rarely compromise vision, although severe
decreases in visual acuity and blindness has been reported
in some cases due to hamartoma enlargement, macular in-
volvement, retinal detachment, and vitreous hemorrhage
(Robertson, 1999).
Multiple cardiac rhabdomyomas are cardiac tumors
most frequently encountered during infancy and childhood
and they occur in approximately 30% of TSC patients. On
the other side, nearly 100% of fetuses with multiple rhabdo-
myomas have TSC. Cardiac rhabdomyomas usually do not
cause symptoms or hemodynamic compromise, and the
natural history for these lesions is spontaneous regression
in the vast majority of cases. However, a minority of the
cases may become symptomatic shortly after birth or in the
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Table 1 - Revised Diagnostic Criteria for Tuberous Sclerosis Complex *.
Major Features
1. Facial angiofibromas or forehead plaque
2. Non-traumatic ungual or periungual fibroma
3. Hypomelanotic macules (more than three)
4. Shagreen patch (connective tissue nevus)
5. Multiple retinal nodular hamartomas
6. Cortical tubera
7. Subependymal nodule
8. Subependymal giant cell astrocytoma




1. Multiple randomly distributed pits in dental enamel
2. Hamartomatous rectal polypsc
3. Bone cystsd
4. Cerebral white matter migration lines a d e
5. Gingival fibromas
6. Non-renal hamartomac
7. Retinal achromic patch
8. “Confetti” skin lesions
9. Multiple renal cystsc
Definite TSC: Either 2 major features or 1 major feature with 2 minor
features
Probable TSC: One major feature and one minor feature
Possible TSC: Either 1 major feature or 2 or more minor features
* Revised Diagnostic Criteria for Tuberous Sclerosis Complex established
by a consortium in 2012 (Northrup et al., 2012).
a When cerebral cortical dysplasia and cerebral white matter migration
tracts occur together, they should be counted as one rather than two fea-
tures of TSC.
b When both lymphangiomyomatosis and renal angiomyolipomas are
present, other features of TSC should be present before a definitive diag-
nosis is assigned.
c Histologic confirmation is suggested.
d Radiographic confirmation is sufficient.
e One panel member recommended three or more radial migration lines
constitute a major feature.
first year of life. Finally, hamartomas may also occur in or-
gans of the endocrine system and rare case reports exist of
angiomyolipomas or fibroadenomas in the pituitary gland,
pancreas, or gonads (O’Callaghan and Osborne, 2010).
Neurological involvement
Neurologic complications are the most common and
often the most impairing aspect of TSC. Structural neuro-
logical abnormalities include cortical tubers, subepen-
dymal nodules (SENs) and subependymal giant cell tumors
(SGCTs). Brain tumors in TSC are rare (2 to 10% of pa-
tients with TSC and 1.1-1.4% of all pediatric brain tumors)
(Frèrebeau et al., 1985). Cortical tubers are developmental
abnormalities present in more than 88% of children with
TSC (Cuccia et al., 2003), and the average number of tubers
per patient ranges from 5 to 50 in different studies. Tubers
lead to loss of the classical six-layered cyto-architecture of
the cerebral cortex and are thought to be responsible for
more than 75% of the epileptic disorders in patients with
TSC (Orphanet: Tuberous Sclerosis). The second more fre-
quent structural neurological lesions in children with TSC
are SENs, which are small hamartomas that occur in the
walls of the lateral ventricles. Only SENs located in the re-
gion of the Monro foramina may have the potentiality to
grow and to transform into SGCTs (5%-20% of patients).
The last but not least important type of encephalic lesion is
SGCT, affecting an average of 10% of children with TSC.
SGCTs are benign, slow-growing tumors of mixed glio-
neuronal cells including giant cells. They are typically lo-
cated near the foramen of Monro, hence they can cause
increased intracranial pressure, obstructive hydrocephalus,
focal neurologic deficits and death (Orphanet: Tuberous
Sclerosis, 2015). Approximately 90% of TSC patients ex-
perience seizures and about 50% have documented cogni-
tive impairment, autism, or other behavioral disorders.
Epilepsy is likely the most prevalent and challenging
clinical manifestation of TSC, and virtually all subtypes of
seizure have been reported. At least one third of patients de-
velop refractory epilepsy; attention deficit-hyperactivity
disorder and psychiatric comorbidities, such as mood disor-
ders, anxiety, obsessive compulsive behavior and alcohol-
ism are also frequently present. Among the different sites of
tumor development, the brain remains undoubtedly the
most problematic in terms of therapeutic management and
screening. Brain tumors are the cause of more than 50% of
deaths among children with TSC (Webb et al., 1996). Intel-
lectual disability has a prevalence of 40%-50% in TSC;
30% are severely affected with IQs in the very low range,
and 70% have IQs in the normal, yet slightly left-shifted
range (Joinson et al., 2003).
Molecular genetics of TSC: the TSC1 and
TSC2 genes
Tuberous sclerosis is caused by mutations in one of
two tumor suppressor genes: TSC1 (9q34) and TSC2
(16p13.3). The TSC1 gene spans about 53kb of genomic
DNA with 23 exons coding for hamartin, a hydrophilic pro-
tein with 1164 amino acids and 130 kDa. Hamartin is ex-
pressed in several adult tissues and plays a key role in the
regulation of cell adhesion. This protein shows no homo-
logy with any other vertebrate protein. The TSC2 gene
comprises approximately 43kb of genomic DNA with 41
exons encoding a 5.5 kb transcript and a 1807 amino acid
protein, tuberin, with 198 kDa. This protein contains a hy-
drophilic N-terminal domain and a conserved 163 amino
acid region encoded by exons 34-38, near the C-terminal
portion, which has homology with the Ras superfamily
GTPases proteins rap1GAP and mSpa1 (Maheshwar et al.,
1997). Therefore, tuberin is a GTPase activating protein
that regulates the GTP binding and hydrolysing activity of
the Ras superfamily of proteins and helps to regulate cell
growth, proliferation and differentiation. The other do-
mains of tuberin are less conserved, and additional homo-
logies between tuberin and other proteins have not been
identified. Serfontein et al. (2011) used bioinformatics
tools to examine the presence of conserved elements of
TSC1 and TSC2 across different organisms. The analyzed
organisms showed a wide range in the degree to which resi-
dues implicated in signalling are conserved (or present at
all) in comparison to the human TSC1 and TSC2 sequences.
Not surprisingly, the mammalian proteins of Rattus
norvegicus and Mus musculus shared the largest number of
residues with the human proteins.
Figure 1A schematically shows the structure of TSC1
and TSC2 genes, their coding exons and the main domains
of hamartin and tuberin. These proteins bind each other via
their respective coiled-coil domains to form an intracellular
complex that integrates signals to control cellular homeo-
stasis, oxygen levels, presence of nutrients, energy pool,
and stimulation by growth factors. Such signals regulate
Rheb (a Ras homologue enriched in brain), responsible for
the activation of mTOR (mammalian target of rapamycin)
kinase. mTOR, in turn, regulates the translation of a signifi-
cant proportion of cellular proteins, including those respon-
sible for the control of cell growth and proliferation
(Kwiatkowski, 2003).
Figure 2 shows the role of the TSC2:TSC1 complex
in the mTOR pathway. Loss of function mutations in TSC1
or TSC2 lead to deregulated expression patterns in this
pathway, abnormal production of the end products, and ul-
timately promote tumorigenesis. To date, specific mecha-
nisms by which these loss of function mutations cause
disease are not established. It is suggested that tumor for-
mation is initiated as a consequence of at least two hits
(Knudson, 1971): as TSC1 and TSC2 are tumor suppressor
TSC mutations: a review 71
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Figure 1 - TSC1 and TSC2 gene structure, domains and distribution of point mutations. (A) Schematic representation of TSC1 and TSC2 exons and the
domains of hamartin and tuberin, respectively, codified by them. The symbols represent the number of different mutations described at each exon. (B)
The graph shows the percentage of the total number of described mutations that occur at each TSC1 and TSC2 exon.
Figure 2 - The role of the TSC2:TSC1 complex in the mTOR pathway. PI3K is activated by growth factors through direct interaction with receptors or
through interaction with scaffolding adaptors, such as the IRS proteins. These interactions recruit PI3K to its substrate PtdIns(4,5)P2 (PIP2), allowing
generation of the lipid second messenger PtdIns(3,4,5)P3 (PIP3). Akt and PDK1 are recruited to the cell plasma membrane through association with PIP3.
This allows Akt to be activated through phosphorylation on Thr308 by PDK1 and Ser473 by mTORC2 (not shown). Once active, Akt phosphorylates
many downstream targets, including multiple sites on TSC2. Phosphorylation of TSC2 impairs the GTPase activity of the TSC2:TSC1 complex, allowing
Rheb-GTP to accumulate. Rheb-GTP in excess activates high levels of mTORC1, which in turn phosphorylates and inhibits 4E-BP1 and activates S6K1
and S6K2. By this way, mTORC1 influences on cell growth, translation factors activation and cell nutrition.
genes, the inactivation of both TSC1 or both TSC2 alleles is
necessary for benign or malignant tumor formation. The
first hit is an inherited germline mutation in TSC1 or TSC2,
which can be detected in approximately 85% of patients
with the clinical features of TSC, and the second hit is so-
matic. There are multiple possible mechanisms for somatic
inactivation of the wild-type alleles of TSC1 and TSC2, in-
cluding loss of heterozygosity, mutation and promoter
methylation. It is possible that epigenetic silencing medi-
ated by micro-RNAs also occurs. Moreover, binding of
TSC1 to TSC2 appears to stabilize intracellular TSC2 lev-
els since uncomplexed TSC2 is subject to ubiquitin-
mediated degradation (Chong-Kopera et al., 2006). Thus,
TSC1 has a role in stabilizing the complex, while TSC2 has
the GTPase activity. For this reason, inactivating mutations
in either gene give rise to the same clinical disorder.
Clearly, both proteins play pivotal roles in several pro-
cesses that are crucial for normal brain development. In ad-
dition, because they are widely expressed throughout the
mature brain, these proteins likely have important homeos-
tatic regulatory functions in neurons during adult life.
Although several TSC families exhibit an autosomal
dominant pattern of inheritance, 70% of the cases result
from de novo germline mutations. Linkage studies initially
suggested that there would be equivalent numbers of fami-
lies with mutations in each TSC gene (Benvenuto et al.,
2000). However, the frequency of mutations reported in
TSC2 is consistently higher than in TSC1; TSC1 mutations
account for only 10% to 30% of the families identified with
TSC. In sporadic TSC, there is an even greater excess of
mutations in TSC2. Nonetheless, identification of TSC1
mutations appears to be twice as likely in familial cases as
in sporadic cases. The disparity in mutational frequency
may reflect an increased rate of germline and somatic muta-
tions in TSC2 as compared with TSC1, as well as an ascer-
tainment bias, since mutations in TSC2 are associated with
more severe disease (Dabora et al., 2001; Jansen et al.,
2008; Kothare et al., 2014). In patients with the TSC phe-
notype and no identifiable mutations in either TSC1 or
TSC2 (15% to 20%), the disease is usually milder (Dabora
et al., 2001). A milder phenotype has also been described in
rare individuals with mosaicism for mutations in TSC1 or
TSC2. Caignec et al. (2009) reported a unique family with
three independent pathogenic mutations in TSC2 mapping
to distinct haplotypes. The three mutations were most likely
de novo, as parents of the affected patients did not present
any features of TSC. In addition, findings consistent with
gonadal mosaicism were seen in one branch of the family.
Molecular diagnosis in TSC
The development of novel techniques and great ad-
vances in high-throughput genetic analysis in the last few
years made mutation screening of the TSC1 and TSC2
genes feasible. Recent massively parallel sequencing tech-
nologies (Next-Generation Sequencing, NGS) and copy
number variation testing (Multiplex Ligation-dependent
Probe Amplification - MLPA and array-Comparative
Genomic Hybridization - aCGH) have been validated for
clinical use in many disorders including TSC, rendering the
analysis much faster and more cost-effective.
Extensive studies of the TSC1 and TSC2 genes in pa-
tients with TSC have revealed a wide spectrum of muta-
tions. We searched the PubMed database to retrieve
available published literature in English from 1998 to 2014
that described mutations at TSC1 and TSC2 genes and es-
tablished genotype-phenotype correlations for tuberous
sclerosis disease. The following keywords were used:
TSC1 mutations; TSC2 mutations; tuberous sclerosis com-
plex; TSC mutations; TSC molecular analysis; genotype-
phenotype correlation on tuberous sclerosis. Twenty-seven
studies were included in the final analysis. Table 2 summa-
rizes the results obtained in the main studies performed
with unrelated TSC patients worldwide; many of the
changes listed were found for the first time in the investi-
gated population. The most frequent mutation type is point
mutations. Large gene rearrangements are less frequently
reported, both because of their true prevalence in TSC and
also because several studies did not use methodologies that
are directed to the identification of such mutations. As ex-
pected, the observed mutation detection rate is not always
complete. In this group, a mutation could exist in an
intronic region distant from the exon-intron boundaries,
which could have an effect on the splicing process or gene
regulation, causing a reduction of normal mRNA tran-
script. Although a third gene for TSC may exist and explain
this lack of mutation at TSC1 and TSC2 genes in some pa-
tients, there is currently no concrete evidence for this. Also,
somatic and germ line mosaicism is a credible explanation
for the failure to detect mutations in some patients, and spe-
cialized methods can be used to enhance detection of these
specific situations. Most studies in TSC patients were con-
ducted in Europe and Asia. The largest cohorts are from the
Netherlands and Poland/USA. As expected through ob-
served mutation frequencies, in all populations described,
the germline mutation rate at the TSC2 locus was higher
than that at the TSC1 locus. Also, the frequency of small re-
arrangements (small insertions/deletions) is higher than
missense, nonsense and splice site mutations in all popula-
tions.
The exponential discovery rate of novel genomic al-
terations that cause TSC stimulated the creation and storage
of genetic information in mutation databases. In the Human
Genome Mutation Database (HGMD) for instance, 30
unique missense and 59 nonsense mutations in TSC1 had
been described by 2014, as well as 91 small deletions, 41
small insertions, 31 splice site mutations and 21 large rear-
rangements. In this database, TSC1 mutations correspond
to 93% of the mutations, with the largest number of these
occurring in exon 15, which is the largest in basepairs
(559). Proportionally, it corresponds to a mutation fre-
TSC mutations: a review 73































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































quency of 9.5% (determined as the percentage of mutations
per base pairs, considering the size of each exon) and the
highest mutation frequency is in exon 13 (14.3%). Con-
sidering all exons, the average frequency of observed muta-
tions is 5.9%. Seven of the 23 exons have higher values
(above 9%). Small deletions are responsible for 41% of the
disease and small insertions, for 18.5%. Large rearrange-
ments are responsible for 7% of mutations in TSC1 at this
database. The predicted coiled-coil domain of hamartin
corresponds to exons 17-23, where 21.9% of the mutations
are localized. Exons 17-18 are responsible for interaction
with tuberin, and they account for 15.9% of the point muta-
tions described. Another database, the Leiden Open Varia-
tion Database (LOVD), reports 690 unique DNA variants
for the TSC1 gene.
Considering the TSC2 gene, 183 unique missense and
125 nonsense mutations gene are described in the HGMD
database, as well as 189 small deletions, 99 small inser-
tions, 120 splice site mutations and 148 large rearrange-
ments. Point mutations correspond to 82.6% of the
mutations, with the largest number of these occurring in
exon 33, which is the largest in basepairs (488). Propor-
tionally, this exon corresponds to a mutation frequency of
15.45%, and the highest mutation frequency is in exon 37
(22.9%) and exon 38 (22.8%). Considering all exons, aver-
age frequency of observed mutations is 11.0%, a higher
number than mutation frequency at the TSC1 gene.
Twenty-seven of the 41 exons have mutation frequency
values above 9% and an overall mutation number and mu-
tation frequency higher than that at the TSC1 gene. Small
deletions are responsible for 32% of the disease versus 41%
in the TSC1 gene, and small insertions for 17% versus
18.5% in the TSC1 gene. Large rearrangements are not
shown in the table, and are responsible for 17.4% of muta-
tions in TSC2, a higher number than the frequency of large
rearrangements in the TSC1 gene.
The predicted coiled-coil domain of tuberin corre-
sponds to exon 10 of the TSC2 gene, where only 1.8% of
small mutations are localized. Exons 34-38 encode the
GAP-domain, responsible for the essential GTPase acti-
vaty, and they account for 18.1% of the point mutations de-
scribed at this gene, with a high mutation frequency
(95.1%). Exons 37 and 38 have shown the highest mutation
frequency in the TSC2 gene, and these mutations can have a
damage effect on the protein since the GAP domain can be
disrupted. In the Leiden Open Variation Database, 1925
unique DNA variants on TSC2 gene have been reported.
Figure 1A illustrates the distribution of point muta-
tions among all exons and domains of the TSC1 and TSC2
genes described in these different studies, and Figure 1B
graphically represents the occurrence of point mutations in
each of the TSC1 and TSC2 exons (percentage of the total
number of described mutations in the HGMD database that
occurs in each exon). This percentage is not related to exon
size, but larger exons contain more mutations than smaller
exons.
Because TSC can be a devastating disease, family
members of affected individuals are often eager to know
whether they are carriers of TSC mutations. Currently, with
the adventure of next generation sequencing platforms, it
became possible to analyze point mutations in both TSC1
and TSC2 genes at the same time for a lower cost; if no mu-
tations are detected, the search for large deletions and du-
plications should proceed. Prenatal and preimplantation
genetic tests are also becoming more widely available. The
mutation status of family members has great implications
on genetic counseling. Furthermore, for all clinical diag-
nostic criteria, patients with subclinical TSC may not be
correctly diagnosed, and genetic testing is also very impor-
tant for these cases.
The second International Tuberous Sclerosis Com-
plex Consensus Conference brought together 79 experts
from 14 countries to finalize diagnostic, surveillance, and
management recommendations for patients with TSC
(Northrup et al., 2013). At this meeting, the most signifi-
cant change recommended was the incorporation of genetic
testing in the diagnostic criteria. Molecular testing of the
TSC1 and TSC2 genes yields a positive mutation result for
75-90% of TSC-affected individuals categorized as having
definite Clinical Diagnostic Criteria. The recommendation
of the Genetics Panel was to make the identification of a
pathogenic mutation in TSC1 or TSC2 an independent diag-
nostic criterion, regardless of the clinical findings. This will
facilitate the diagnosis of TSC in some, particularly young
individuals, allowing earlier implementation of surveil-
lance and treatment with a potential for better clinical out-
comes. TSC1 and TSC2 genetic variants whose functional
effect is not definitely pathogenic would not be considered
a major diagnostic criterion. Finally, a normal result from
TSC1 and TSC2 testing does not exclude TSC, since a frac-
tion of TSC patients has no mutation identified by conven-
tional genetic testing. Nonetheless, if the mutation in an
affected relative is known, testing for that mutation has
very high predictive value for family members.
Genotype-phenotype correlations in TSC
The discovery of the underlying genetic defects in
TSC has furthered our understanding of this complex ge-
netic disorder and genotype-phenotype correlations are be-
coming possible. In a retrospective study, Kothare et al.
(2014) analysed a series of 919 TSC patients and found that
carriage of a germline TSC2 mutation was associated with
SENs and SGCTs. Occurrence of tubers, however, did not
differ between carriers of TSC1 or TSC2 mutations. In gen-
eral, patients with TSC2 mutation presented with symptoms
at a younger age. Dabora et al. (2001) analyzed 224 TSC
patients and found that seizures, average cortical tuber
number and SEN are more frequent or severe in patients
with de novo TSC2 mutations than those with TSC1 muta-
TSC mutations: a review 75
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Table 3 - Genotype-phenotype correlations established for TSC patients.
Population N Locus of DNA alteration Amino
acid change
Type of alteration Main associated
symptoms
Reference
EUA 1039 TSC2 - Any type on TSC2 Mutations in the TSC2
gene were more frequent
than TSC1 gene in patients
with retinal findings
(Aronow et al., 2012)
Poland 170 TSC2 c.5238-5255del
18pb
- Frameshift Epilepsy (Rok et al., 2005)






(Boronat et al., 2014)
Poland/USA 224 TSC2 - Any type on TSC2 Seizures, mental retarda-





more common and severe
in TSC2 patients
(Dabora et al., 2001)
Netherlands 490 TSC1 - Any type on TSC1 Shagreen patches are more
frequent in patients with
TSC1 mutation
(Sancak et al., 2005)
Netherlands 490 TSC2 - Any type on TSC2 Mental retardation is more
frequent in patients with
TSC2 mutation
(Sancak et al., 2005)








(Sancak et al., 2005)




(Sancak et al., 2005)
Korea 11 TSC2 - Mutations in exons
33-41
Cardiac rhabdomyomas (Jang et al., 2012)
USA 65 TSC2 - Any type on TSC2 Higher number of cysts
than TSC1 woman with
pulmonary
lymphangioleiomyomatosis
(Muzykewicz et al., 2009)
Canada 19 families TSC2 R905Q Missense Milder disease severity (Jansen et al., 2006)
USA 478 TSC2 proximal region






Proximal and distal TSC2
mutations showed a signifi-
cantly higher risk of infan-
tile spasms compared with
mutations in the central re-
gion of the gene
(van Eeghena et al., 2013)
USA and
Belgium
919 TSC2 - Any type on TSC2 More frequent occurrence




spasms, SENs, SGCTs and
cognitive impairment.










and small number of
hypomelanotic macules)
(Blyth et al., 2010)
N= number of patients included in the study.
NI=Not informed.
tions. Jansen et al. (2008) also reported a more severe neu-
rologic phenotype, including an earlier age of seizure onset,
lower cognition index and more tubers in patients with a
TSC2 mutation as compared to those with a TSC1 mutation.
Another important correlation involves a subgroup of large
genomic deletions at TSC2 that also affect the adjacent
PKD1 gene, causing early-onset polycystic kidney disease
(Osborne et al., 1991).
Table 3 shows a compilation of the main genotype-
phenotype correlations described to date. As expected,
most TSC2 mutations are generally associated with a more
severe phenotype. Only one TSC2 mutation, R905Q, was
associated with milder disease. This mutation was found in
25 individuals from the same family, with a phenotype
characterized by the complete absence of disfiguring skin
lesions, intractable epilepsy, mental retardation, and severe
organ involvement. So, the type and location of mutations
in both TSC1 and TSC2 genes also have an influence in the
phenotype. Hamartin and tuberin are known to bind to at
least 40 additional proteins, and thus there are numerous
potential and yet undefined effects of TSC gene mutations.
Futhermore, it is likely that other events such as mosaicism,
the nature and frequency of the second event of inactivation
of the second allele and the modifying genes, as well as en-
vironmental effects may interfere with the phenotype,
which makes it more difficult to establish clear genotype-
phenotype correlations. Moreover, polymorphic and non-
pathogenic variants in the TSC1 and TSC2 genes can act as
phenotype modifiers in tuberous sclerosis, and they need to
be further explored. To date, little is known about non-
pathogenic variants in these genes, and phenotype modifi-
ers in tuberous sclerosis have not been identified so far.
In light of emerging human genetic and molecular
knowledge, molecular diagnosis of TSC and determination
of genotyope-phenotype correlations might help in the es-
tablishment of personalized treatment for TSC patients and
improve quality of life among these patients. Continuous
studies in this area can guide future directions in this line.
References
Ali M, Girimaji SC, Markandaya M, Shukla AK, Sacchidanand S
and Kumar A (2005) Mutation and polymorphism analysis
of TSC1 and TSC2 genes in Indian patients with tuberous
sclerosis complex. Acta Neurol Scand 111:54-63.
Apak A, Haliloolu G, Kose G, Yilmaz E, Anlar B and Aysun S
(2003) Mutation analysis of TSC2 gene in 33 Turkish famil-
ial cases with tuberous sclerosis. Turk J Pediatr 45:1-5.
Aronow ME, Nakagawa JA, Gupta A, Traboulsi EI and Singh AD
(2012) Tuberous sclerosis complex: Genotype/phenotype
correlation of retinal findings. Ophthalmology 119:1917-
1923.
Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle
JP, Halley DJ, Sampson JR, Wienecke R and DeClue JE
(2000) The tuberous sclerosis-1 (TSC1) gene product ha-
martin suppresses cell growth and augments the expression
of the TSC2 product tuberin by inhibiting its ubiquitination.
Oncogene 19:6306-6316.
Blyth M, Raponi M, Treacy R, Raymond FL, Yates JR and Baralle
D (2010) Expanding the tuberous sclerosis phenotype: Mild
disease caused by a TSC1 splicing mutation. J Neurol
Neurosurg Psychiatry 81:350-352.
Boronat S, Caruso P, Auladell M, Van Eeghen A and Thiele EA
(2014) Arachnoid cysts in tuberous sclerosis complex. Brain
Dev 36:801-806.
Caignec CL, Kwiatkowski DJ, Kury S, Hardouin JB, Melki J and
David A (2009) Three independent mutations in the TSC2
gene in a family with tuberous sclerosis. Eur J Hum Genet
17:1165-1170.
Castro M, Sheperd CW, Gomez MR and Lie JT (1995) Pulmonary
tuberous sclerosis. Chest 107:189-195.
Choi JE, Chae JH, Hwang YS and Kim KJ (2006) Mutational
analysis of TSC1 and TSC2 in Korean patients with tuberous
sclerosis complex. Brain Dev 28:440-446.
Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa
JL and Guan KL (2006) TSC1 stabilizes TSC2 by inhibiting
the interaction between TSC2 and the HERC1 ubiquitin
ligase. J Biol Chem 281:8313-8316.
Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F and
Taratuto AL (2003) Subependymal giant cell tumor in chil-
dren with tuberous sclerosis. Childs Nerv Syst 19:232-243.
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J,
Choy YS, Reeve MP, Thiele E, Egelhoff JC, et al. (2001)
Mutational analysis in a cohort of 224 tuberous sclerosis pa-
tients indicates increased severity of TSC2, compared with
TSC1 disease in multiple organs. Am J Hum Genet 68:64-
80.
Dixon BP, Hulbert JC and Bissler JJ (2011) Tuberous sclerosis
complex renal disease. Nephron Exp Nephrol 118:15-20.
Frèrebeau P, Benezech J, Segnarbieux F, Harbi H, Desy A and
Marty-Double CH (1985) Intraventricular tumors in tuber-
ous sclerosis. Childs Nerv Syst 1:45-48.
Gumbinger C, Rohsbach CB, Schulze-Bonhage A, Korinthenberg
R, Zentner J, Häffner M and Fauser S (2009) Focal cortical
dysplasia: A genotype-phenotype analysis of polymor-
phisms and mutations in the TSC genes. Epilepsia 50:1396-
1408.
Hung CC, Su YN, Chien SC, Liou HH, Chen CC, Chen PC, Hsieh
CJ, Chen CP, Lee WT, Lin WL, et al. (2006) Molecular and
clinical analyses of 84 patients with tuberous sclerosis com-
plex. BMC Med Genet 7:e72.
Ismail NFD, Malik NMANA, Mohseni J, Rani AM, Hayati F,
Salmi AR, Narazah MY, Zabidi-Hussin ZA, Silawati AR,
Keng WT, et al. (2014) Two novel gross deletions of TSC2
in Malaysian patients with Tuberous Sclerosis Complex and
TSC2/PKD1 Contiguous Deletion Syndrome. Jpn J Clin
Oncol 44:506-511.
Jang MA, Hong SB, Lee JH, Lee MH, Chung MP, Shin HJ, Kim
JW and Ki CS (2012) Identification of TSC1 and TSC2 mu-
tations in Korean patients with Tuberous Sclerosis Com-
plex. Pediatr Neurol 46:222-224.
Jansen AC, Sancak O, D’Agostino MD, Badhwar A, Roberts P,
Gobbi G, Wilkinson R, Melanson D, Tampieri D and Koe-
nekoop R (2006) Unusually mild tuberous sclerosis pheno-
type is associated with TSC2 R905Q mutation. Ann Neurol
60:528-539.
TSC mutations: a review 77
Jansen FE, Braams O, Vincken KL, Algra A, Anbeek P, Jen-
nekens-Schinkel A, Halley D, Zonnenberg BA, van den
Ouweland A, van Huffelen AC, et al. (2008) Overlapping
neurologic and cognitive phenotypes in patients with TSC1
or TSC2 mutations. Neurology 70:908-915.
Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T and
Bolton PF (2003) Learning disability and epilepsy in an epi-
demiological sample of individuals with tuberous sclerosis
complex. Psychol Med 33:335-344.
Jones AC, Shyamsundar MM, Thomas MW, Maynard J,
Idziaszczyk S, Tomkins S, Sampson JR and Cheadle JP
(1999) Comprehensive mutation analysis of TSC1 and
TSC2 - and phenotypic correlations in 150 families with tu-
berous sclerosis. Am J Hum Genet 64:1305-1315.
Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R and
Chmielik J (1998) Skin lesions in children with tuberous
sclerosis complex: Their prevalence, natural course, and di-
agnostic significance. Int J Dermatol 37:911-917.
Knudson AG (1971) Mutation and cancer: Statistical study of reti-
noblastoma. Proc Natl Acad Sci U S A 68:820-823.
Kothare SV, Singh K, Chalifoux JR, Staley BA, Weiner HL,
Menzer K and Devinsky O (2014) Severity of manifesta-
tions in tuberous sclerosis complex in relation to genotype.
Epilepsia 55:1025-1029.
Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T,
Hayashi S, Minami M, Uekusa T, Fukuchi Y, et al. (2004)
Lymphangiogenesis in lymphangioleiomyomatosis: Its im-
plication in the progression of lymphangioleiomyomatosis.
Am J Surg Pathol 28:1007-1016.
Kwiatkowska J, Jozwiak S, Hall F, Henske EP, Haines JL, McNa-
mara P, Braiser J, Wigowska-Sowinska J, Kasprzyk-Obara
J, Short MP, et al. (1998) Comprehensive mutational analy-
sis of the TSC1 gene: Observations on frequency of muta-
tion, associated features, and nonpenetrance. Ann Hum
Genet 62:277-285.
Kwiatkowski DJ (2003) Rhebbing up mTor: New insights on
TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Cancer Biol Ther 2:471-476.
Langkau N, Martin N, Brandt R, Zügge K, Quast S, Wiegele G,
Jauch A, Rehm M, Kuhl A, Mack-Vetter M, et al. (2002)
TSC1 and TSC2 mutations in tuberous sclerosis, the associ-
ated phenotypes and a model to explain observed
TSC1/TSC2 frequency ratios. Eur J Pediatr 161:393-402.
Maheshwar M, Cheadle JP, Jones AC, Myring J, Fryer AE, Harris
PC and Sampson JR (1997) The GAP-related domain of
tuberin, the product of the TSC2 gene, is a target for
missense mutations in tuberous sclerosis. Hum Mol Genet
6:1991-1996.
Mi CR, Wang H, Jiang H, Sun RP and Wang GX (2014) Mutation
screening of TSC1 and TSC2 genes in Chinese Han children
with tuberous sclerosis complex. Genet Mol Res 13:2102-
2106.
Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J and
Thiele EA (2009) TSC1 and TSC2 mutations in patients with
lymphangioleiomyomatosis and tuberous sclerosis com-
plex. J Med Genet 46:465-468.
Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J,
Beauchamp RL, Sims K, Ramesh V and Ozelius L (1999)
Analysis of both TSC1 and TSC2 for germline mutations in
126 unrelated patients with tuberous sclerosis. Hum Mutat
14:412-422.
Northrup H, Wheless JW, Bertin TK and Lewis RA (1993) Vari-
ability of expression in tuberous sclerosis. J Med Genet
30:41-43.
Northrup H, Krueger DA and International Tuberous Sclerosis
Complex Consensus Group (2013) Tuberous sclerosis com-
plex diagnostic criteria update: Recommendations of the
2012 International Tuberous Sclerosis Complex Consensus
Conference. Pediatr Neurol 49:243-254.
O’Callaghan F and Osborne J (2010) Endocrine, gastrointestinal,
hepatic, and lymphatic manifestations of tuberous sclerosis
complex. In: Kwiatkowski D, Whittemore V and Thiele E
(eds) Tuberous Sclerosis Complex: Genes, Clinical Fea-
tures, and Therapeutics. Wiley-Blackwell, Weinheim, pp
369-385.
Osborne JP, Fryer A and Webb D (1991) Epidemiology of tuber-
ous sclerosis. Ann NY Acad Sci 615:25-127.
Qin W, Chan JA, Vinters HV, Mathern GW, Franz DN, Taillon
BE, Bouffard P and Kwiatkowski DJ (2010) Analysis of
TSC cortical tubers by deep sequencing of TSC1, TSC2 and
KRAS demonstrates that small second-hit mutations in these
genes are rare events. Brain Pathol 20:1096-1105.
Rendtorff ND, Bjerregaard B, Frodin M, Kjaergaard S, Hove H,
Skovby F, Brøndum-Nielsen K, Schwartz M and Danish Tu-
berous Sclerosis Group (2005) Analysis of 65 Tuberous
Sclerosis complex (TSC) patients by TSC2 DGGE,
TSC1/TSC2 MLPA, and TSC1 Long-Range PCR Sequen-
cing, and report of 28 novel mutations. Hum Mutat 26:374-
383.
Roach ES, Gomez MR and Northrup H (1998) Tuberous sclerosis
complex consensus conference: Revised clinical diagnostic
criteria. J Child Neurol 13:624-628.
Robertson DM (1999) Ophthalmic findings. In: Gomez MR,
Sampson JR and Whittemore VH (eds) Tuberous Sclerosis
Complex. 3rd ed. Oxford University Press, New York, pp
145-159.
Rok P, Kasprzyk-Obara J, Domanska-Pakiela D and Józwiak S
(2005) Clinical symptoms of tuberous sclerosis complex in
patients with an identical TSC2 mutation. Med Sci Monit
11:230-234.
Rowley SA, O’Callaghan FJO and Osborne JP (2001) Ophthalmic
manifestations of tuberous sclerosis: A population based
study. Br J Ophthalmol 85:420-423.
Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Chea-
dle JP, Ravine D, Roy S, Haan E, Bernstein J and Harris PC
(1997) Renal cystic disease in tuberous sclerosis: Role of the
polycystic kidney disease 1 gene. Am J Hum Genet 61:843-
851.
Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C,
Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D and van
den Ouweland A (2005) Mutational analysis of the TSC1
and TSC2 genes in a diagnostic setting: Genotype-pheno-
type correlations and comparison of diagnostic DNA tech-
niques in Tuberous Sclerosis Complex. Eur J Hum Genet
13:731-741.
Sasongko TH, Wataya-Kaneda M, Koterazawa K, Gunadi,
Yusoff S, Harahap IS, Lee MJ, Matsuo M and Nishio H
(2008) Novel mutations in 21 patients with tuberous sclero-
sis complex and variation of tandem splice-acceptor sites in
TSC1 exon 14. Kobe J Med Sci 54:73-81.
78 Rosset et al.
Schwartz RA, Fernandez G, Kotulska K and Jozwiak S (2007) Tu-
berous sclerosis complex: Advances in diagnosis, genetics,
and management. J Am Acad Dermatol 57:189-202.
Serfontein J, Nisbet R, Howe CJ and de Vries PJ (2011) Conserva-
tion of structural and functional elements of TSC1 and
TSC2: A bioinformatic comparison across animal models.
Behav Genet 41:349-356.
Shepherd CW, Gomez MR, Lie JT and Crowson CS (1991)
Causes of death in patients with tuberous sclerosis. Mayo
Clin Proc 66:792-796.
Sun XF, Yan CL, Fang L, Shen FM and Liao KH (2005) Cutane-
ous lesions and visceral involvement of tuberous sclerosis.
Chin Med J (Engl) 118:215-219.
Tian H, Wang X, Wu M, Zhou G and Lu X (2013) Three novel
mutations of TSC1 gene in Chinese patients with tuberous
sclerosis complex. Int J Dermatol 52:1274-1290.
van Eeghena AM, Nellist M, van Eeghena EE and Thiele EA
(2013) Central TSC2 missense mutations are associated with
a reduced risk of infantile spasms. Epilepsy Res 103:83-87.
Webb DW, Fryer AE and Osborne JP (1996) Morbidity associ-
ated with tuberous sclerosis: A population study. Dev Med
Child Neurol 38:146-155.
Yamamotoa T, Pipob JR, Fengb JH, Takeda H, Nanba E, Nino-
miya H and Ohno K (2002) Novel TSC1 and TSC2 muta-
tions in Japanese patients with tuberous sclerosis complex.
Brain Dev 24:227-230.
Yates JR (2006) Tuberous sclerosis. Eur J Hum Genet 14:1065-
1073.
You J, Liu H, Fu X, Chen M, Niu G, Tian H and Zhang F (2013)
Two novel TSC2 mutations in Chinese patients with tuber-
ous sclerosis complex. Indian J Dermatol Venereol Leprol
79:104-105.
Internet resources
HGMD - Human Genome Mutation Database,
http://www.hgmd.cf.ac.uk/ac/index.php (accessed in No-
vember, 2014).
LOVD - Leiden Open Variation Database







Associate Editor: Carlos F. M. Menck
License information: This is an open-access article distributed under the terms of the
Creative Commons Attribution License (type CC-BY), which permits unrestricted use,
distribution and reproduction in any medium, provided the original article is properly cited.
TSC mutations: a review 79
